Castration-resistant prostate cancer
2 papers
- Cells1
Trial sponsors
Company3 trialsPhase 31,201 people
Company1 trialPhase 1/25 people
Company1 trialPhase 130 people
Company1 trialPhase 114 people
Ottawa Hospital Research Institute
1 trialPhase 4240 people
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3 trialsPhase 264 people
1 trialPhase 2532 people
1 trialPhase 2220 people
Latest
4 in 12 monthsWorld Journal of Urology
Frailty and comorbidity surpass probable sarcopenia in predicting survival of mCRPC patients treated with first-line ARPIs: a comprehensive geriatric analysis
Cohort study of 213 peopleSarcopenia
bioRxiv
p21 CIP1/WAF1 -mediated partial senescence supports steroidogenesis and therapy resistance in primary prostate cancer cultures
Preprint: experiments in cellsMechanisms
Cancer Treatment Reviews
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer
ReviewCellular senescence
Cancer Genomics & Proteomics
Verbascoside Suppresses Epithelial-Mesenchymal Transition and Mitochondrial Biogenesis by Targeting Anti-senescence Signaling in Castration-resistant Prostate Cancer
Experiments in human cellsProstate cancer